Imatinib Mesylate 400mg Tablets
Imatinib mesylate tablets are an antineoplastic medicament used primarily for treating chronic myeloid leukemia by inhibiting tyrosine kinase activity. They are put up in measured doses of 400mg per tablet in retail packaging, qualifying under HTS 3004.90.92.16 as an unmixed antineoplastic product for therapeutic use.
Import Duty Rates by Country of Origin
Alternative Classifications
This product could be classified differently depending on its characteristics or intended use.
If imported in bulk powder form without measured doses or retail packing
Bulk heterocyclic compounds like imatinib fall under Chapter 29 as chemical substances, not finished medicaments.
If classified as a mixed product containing hormones or steroids
Medicaments with hormonal components are directed to heading 3003, separate from other mixed therapeutic products.
If for other therapeutic uses excluding antineoplastic or immunosuppressive
Non-cancer or non-immunosuppressive medicaments in measured doses go to the general 'other' category within 3004.90.
Not sure which classification is right?
Our AI classifier can analyze your specific product and recommend the correct HTS code with confidence.
Import Tips & Compliance
• Verify FDA approval and provide certificates of analysis confirming active ingredient purity to avoid detention at customs
• Ensure labeling complies with 21 CFR 201 for prescription drugs, including lot numbers and expiry dates
Related Products under HTS 3004.90.92.16
Tacrolimus 1mg Capsules
Tacrolimus capsules are immunosuppressive medicaments used to prevent organ transplant rejection, containing 1mg of the active ingredient in hard gelatin capsules for oral measured doses. Classified under HTS 3004.90.92.16 for retail-packed immunosuppressive products.
Mycophenolate Mofetil 500mg Tablets
Mycophenolate mofetil is an immunosuppressive prodrug inhibiting lymphocyte proliferation, used post-transplant in 500mg enteric-coated tablets. Under HTS 3004.90.92.16 for retail-packaged measured medicaments.
Pembrolizumab 100mg/4ml Solution
Pembrolizumab injection is an anti-PD-1 antineoplastic monoclonal antibody for various cancers, in 100mg/4ml vials for IV infusion. HTS 3004.90.92.16 applies to these dosed immunosuppressive therapies.
Cyclophosphamide 50mg Injection Vials
Cyclophosphamide is an immunosuppressive and antineoplastic agent used in chemotherapy for cancers and autoimmune diseases, supplied in sterile 50mg vials for measured dosing. It fits HTS 3004.90.92.16 as a put-up unmixed product for therapeutic retail sale or hospital use.
Rituximab 100mg/10ml Intravenous Infusion
Rituximab is a monoclonal antibody antineoplastic used for non-Hodgkin lymphoma and rheumatoid arthritis, provided in 100mg/10ml single-use vials for measured IV administration. It qualifies under HTS 3004.90.92.16 as an immunosuppressive biologic in dosed form.
Methotrexate 2.5mg Tablets
Methotrexate tablets are antineoplastic and immunosuppressive drugs used for cancer, psoriasis, and rheumatoid arthritis in low-dose 2.5mg scored tablets for precise therapeutic dosing. Falls under HTS 3004.90.92.16 for measured retail medicaments.